MedTrace Logo

Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria

NCT02166151 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-06-18

No results posted yet for this study

Summary

The study is designed to assess the efficacy and safety of monthly injections of Omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or oral corticosteroids.

Conditions

  • Chronic Idiopathic Urticaria

Interventions

DRUG

Omalizimab

Omalizimab 150 mg S.C. once a month for consecutive 3 months

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Michael David, Prof · Rabin Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02166151 on ClinicalTrials.gov